SPYH:XETRA:XETRA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 181.72

Change

-12.04 (-6.21)%

Market Cap

N/A

Volume

676.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-09 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

+0.53 (+1.23%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.92 (-1.02%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.44 (+2.00%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

+0.17 (+1.39%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

+0.07 (+1.42%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

+0.19 (+0.87%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

-0.17 (-1.45%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

-0.42 (-0.74%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

-0.08 (-0.82%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

+0.32 (+0.27%)

USD 12.26B

ETFs Containing SPYH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.14% 41% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.14% 43% F 41% F
Trailing 12 Months  
Capital Gain -14.61% 16% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.61% 17% F 22% F
Trailing 5 Years  
Capital Gain 21.41% 42% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.41% 43% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 9.35% 61% D- 61% D-
Dividend Return 9.35% 60% D- 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.91% 71% C- 77% C+
Risk Adjusted Return 118.21% 96% N/A 96% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike